Blockchain Registration Transaction Record

Lantern Pharma’s LP-300 Shows Promising Progression-Free Survival in Lung Cancer

Lantern Pharma's LP-300 shows improved progression-free survival in EGFR L858R-mutant lung cancer patients. Updated Phase 2 HARMONIC trial data supports extended dosing. AI-driven precision oncology.

This news matters because it highlights a potential new treatment option for patients with EGFR Exon 21 L858R-mutant non-small cell lung cancer who have exhausted TKI therapy. The improved progression-free survival and clean safety profile could address a significant unmet need in this specific patient population. Additionally, Lantern’s AI-driven approach, including the commercially available withZeta.ai platform, signals a shift toward more efficient and targeted drug development, which could accelerate the delivery of effective therapies to patients.